After a tumultuous year, a popular virtual care platform is trying its hand in a competitive blood testing market.

CHICAGO (Reuters) -Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's disease protein that can appear years ...

Quest Diagnostics will soon begin offering a new blood-based in-vitro diagnostic test for Alzheimer’s. The disease affects nearly 7 million Americans. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma ...

Quest Diagnostics unveiled a first-to-market blood test available for consumer purchase that helps assess the potential risk of developing Alzheimer’s disease. In adding AD-Detect, a single-blood-draw ...

Dr. Michael Racke, a neurologist and Medical Director of Neurology with Quest Diagnostics, speaks on Studio10 about Quest Diagnostic’s new blood test that can detect Alzheimer's. The test is a blood ...

Please provide your email address to receive an email when new articles are posted on . Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for ...

Quest Diagnostics Inc. said Monday the first blood-based biomarker test to assess the risk of developing Alzheimer’s disease is now available for consumer purchase. The test helps assess the risk of ...

Quest Diagnostics Incorporated (NYSE:DGX) is one of the 7 most undervalued pot stocks to buy according to analysts. On June 10, the company said it is developing a Multi-Cancer Stratification (MCaST) ...

The telehealth platform expects the new offering to add to its user base as it draws customers looking to prevent future ...

Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...